PRELUDE THERAPEUTICS INC Debt Securities, Available-for-sale, Unrealized Loss Position
PRELUDE THERAPEUTICS INC (PRLD) had Debt Securities, Available-for-sale, Unrealized Loss Position of $125.40 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Debt and Equity Securities
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition · last filed 2026-08-11
- 2026-06-30: Debt Securities, Available-for-sale, Unrealized Loss Position $125.40M.
- 2026-03-31: Debt Securities, Available-for-sale, Unrealized Loss Position $52.30M.
- 2025-12-31: Debt Securities, Available-for-sale, Unrealized Loss Position $33.10M.
- 2025-09-30: Debt Securities, Available-for-sale, Unrealized Loss Position $1.40M.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss Position |
|---|---|
| 2026-06-30 | $125.40M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $52.30M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $33.10M 10-K · filed 2026-03-10 |
| 2025-09-30 | $1.40M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $26.40M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $31.20M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $18.60M 10-K · filed 2025-03-10 |
| 2024-09-30 | $23.00M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $144.80M 10-Q · filed 2024-08-12 |
| 2024-03-31 | $166.30M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $75.60M 10-K · filed 2024-02-15 |
| 2023-09-30 | $193.40M 10-Q · filed 2023-11-01 |
| 2023-06-30 | $199.10M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $138.50M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $163.60M 10-K · filed 2023-03-15 |
| 2021-12-31 | $221.80M 10-K · filed 2022-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |